New Medicare Drug Pay Model Invites Industry Clash
Law360, New York (March 8, 2016, 9:32 PM EST) -- Federal regulators on Tuesday proposed a nationwide, five-year test of new drug payment policies aimed at cutting costs in Medicare Part B, likely touching off a significant fight with drugmakers, doctors and hospitals.
The proposal would affect most health care providers that bill for Part B drugs, which tend to be injectables or infusion products administered in professional settings. Under the plan, providers would be placed randomly into one of four groups: three that use new payment models, and one that uses the existing model and serves as a control group.
The existing model pays providers the so-called average sales price...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!